New Frontiers in Osteoporosis Therapy

Area of Science:

• Bone biology and genetics
• Pharmacology
• Regenerative medicine

Background:

• Current osteoporosis drugs have rare but severe side effects, limiting long-term use.
• Advances in bone biology and genetics are driving new therapeutic strategies.
• Osteoporosis management requires balancing efficacy with safety concerns.

Purpose of the Study:

• To review recent advances in osteoporosis therapeutics.
• To highlight novel anabolic agents and combination treatment strategies.
• To discuss emerging cell-based and senolytic therapies.

Main Methods:

• Review of clinical trial data for romosozumab and abaloparatide.
• Analysis of sequential and combination treatment approaches.
• Exploration of preclinical and emerging therapeutic concepts.

Main Results:

• Romosozumab demonstrates significant antifracture benefits.
• Abaloparatide builds on teriparatide experience, emphasizing consolidation of gains.
• Combination and sequential therapies show promising results.

Conclusions:

• Novel agents like romosozumab and abaloparatide represent significant progress in osteoporosis treatment.
• Strategic use of anabolic agents followed by antiresorptives is crucial.
• Future research directions include cell-based therapies and senolytics for bone regeneration and microenvironment modulation.